Key result
Patients with calcific aortic valve disease had significantly lower serum t-ucMGP levels compared to healthy controls (29.29 vs 36.84 nmol/l, p=0.003).
Why the study?
Low levels of circulating total uncarboxylated Matrix Gla protein (t-ucMGP) indicate prevalent vascular calcification, prompting investigation into whether t-ucMGP can serve as a biomarker to identify patients with calcific aortic valve disease.
Are serum t-ucMGP levels lower in patients with calcific aortic valve disease compared to healthy controls?
Cross-Sectional (n=71)
Yes
Are serum t-ucMGP levels lower in patients with calcific aortic valve disease compared to healthy controls?
Absolute Event Rate: 29.29% vs 36.84%
p-value: p=0.003
Lower t-ucMGP levels were associated with calcific aortic valve disease; leaves open its utility as a noninvasive biomarker.
Background: Calcific aortic valve disease (CAVD) is a major contributor to cardiovascular morbidity and mortality. Circulating total uncarboxylated Matrix ?-carboxyglutamate (Gla) protein (t-ucMGP) is a promising biomarker for rapid screening of subjects prone to cardiovascular calcification who may need more invasive vascular diagnostics. Preliminary data show that low t-ucMGP levels are indicative for prevalent vascular calcification. Hence, the aim of our study was to investigate the possible role of circulating t-ucMGP as a biomarker may help in identification patients with CAVD, taking into consideration that CAVD is a form of vascular calcification.Methods & Materials: We analyzed serum t-ucMGP levels by enzyme-linked immunosorbent assay (ELISA) in 50 patients with echocardiographically proven CAVD and 21 control subjects.Results: Serum t-ucMGP levels were significantly lower in patients with CAVD (29.29±12.18 nmol/l) compared to the control group (36.84±21.79 nmol/l, p = 0.003).Conclusion: Serum t-ucMGP may help as a noninvasive biomarker for identification of these patients.
No takes yet. Share an insight, caveat, or question.
Nawasreh et al. (2019) conducted a cross-sectional in Calcific Aortic Valve Disease (n=71). Calcific Aortic Valve Disease vs. Healthy controls was evaluated on Serum t-ucMGP levels (p=0.003). Patients with calcific aortic valve disease had significantly lower serum t-ucMGP levels compared to healthy controls (29.29 vs 36.84 nmol/l, p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: